List of Amturnide drug patents

Amturnide is owned by Novartis.

Amturnide contains Aliskiren Hemifumarate; Amlodipine Besylate; Hydrochlorothiazide.

Amturnide has a total of 1 drug patent out of which 0 drug patents have expired.

Amturnide was authorised for market use on 21 December, 2010.

Amturnide is available in tablet;oral dosage forms.

The generics of Amturnide are possible to be released after 16 May, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8183295 NOVARTIS Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
May, 2023

(3 months from now)

Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE ingredient

Market Authorisation Date: 21 December, 2010

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic